Therefore, our real-world study is the first clinical observational study in China to evaluate the efficacy and safety of epirubicin and cyclophosphamide (EC) with pyrotinib as the main anti-HER2 therapy in neoadjuvant therapy for patients with HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.